期刊文献+

抗丙肝药物faldaprevir的合成

Synthesis of an anti-hepatitis C drug,faldaprevir
原文传递
导出
摘要 目的:抗丙肝新药faldaprevir的合成。方法:以1-(2-氨基-3-溴-4-甲氧基苯基)乙酮为原料经缩合,环化,取代反应,芳香亲核取代,氨基酸缩合和水解反应制得faldaprevir。结果:最终产物faldaprevir经1H-NMR和ESI-MS确证化学结构正确。纯度经HPLC检测可达99.9%,路线总收率达34.8%。结论:该合成工艺操作简单,条件温和,产物纯度好,收率高,适合用于工业化生产。 Objective: To synthesize the anti-hepatitis C drug, faldaprevir. Methods: Using 1-(2-Amino- 3-bromo-4-methoxyphenyl) ethanone as start material, the synthesis consisted of one condensation step, one quinolone cyclic condensation step, two nucleophilic aromatic substitution steps, one amide bond formations step and one hydrolysis step of methyl ester. Results: The verified target material faldaprevir was synthesized with a total yield of 34.8% , and the purity was 99.9% as determined by HPLC. Conclusion: With high purity and yield, this synthetic process is easy to operate in a mild condition, h is suitable for further industrial production.
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第4期452-456,共5页 Chinese Journal of New Drugs
关键词 丙型肝炎 faldaprevir 合成 hepatitis C faldaprevir synthesis
  • 相关文献

参考文献12

  • 1高传义,李勇,惠守红,徐莹.慢性丙型肝炎病毒感染治疗药物研究进展[J].中国实用医药,2010,5(31):250-252. 被引量:1
  • 2FERENCI P,ASSELAH T, FOSTER GR, et al. Faldaprevirplus pegylated interferon alfa-2a and ribavirin in chronic HCVgenotype-1 treatment-naive patients : final results from START-Versol , a randomised, double-blind, placebo-controlled phaseIIItrial [ C ]. The 48th Annual Meeting of the European Associa-tion for the Study of the Liver; April 24-28,2013 ; Amsterdam,the Netherlands. Abstract 1416.
  • 3CHIESEK S, VON HT, MANNS MP, et al. Second-wave Prote-ase Inhibitors: Choosing an Heir[ J]. Clin Liver Dis, 2011 : 15(3): 597 -609.
  • 4LILNAS-B M, BAILEY MD, GOUDREAU N, et al. Discoveryof a potent and selective noncovalent linear inhibitor of the hepati-tis C virus NS3 protease ( BI 201335 ) [ J ]. y Med Chem,2010,53(17) : 6466 -6476.
  • 5西洛.伯肯布希,伯克哈德耶格,卡尔.A.巴萨卡.强效hcv抑制剂2-噻唑基4-喹啉基-氧基衍生物的结晶形式:中国200980136131. [P], 2009 -09 - 14.
  • 6BUSACCA CA, WEI X, HADDAD N, et al. Practical large-scale synthesis of the hepatitis C virus protease inhibitor BI201335[J]. Asian J Org Chem, 2012,1(1): 80 -89.
  • 7VACHON ML. BI-201335 Treatment of hepatitis C virus serineprotease NS3/non-structural protein 4 A ( NS4 A ) inhibitor [ J ].Drug Future,2012 , 37( 2) : 99 - 109.
  • 8CARL AB, ROGELIO PF, NIZAR H. Process for preparing acy-clic hcv pro tease inhibitor: US, 12/335,157 [ P]. 2005 - 05 - 23.
  • 9NITINCHANDRA DP, SENANAYAKE CH, WEI XD. Processfor preparing sulfonyl quinolines: US 13/256 ,752 [ P]. 2010 -03 -18.
  • 10蒙特斯.利纳斯.布鲁尼特,默里.D.贝利,普尼特.巴德瓦.包含丙型肝炎抑制剂化合物的药物组合物:中国201310097223 [P]. 2004 -05 -19.

二级参考文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部